Bolt Biotherapeutics, Inc. (BOLT) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BOLT Insider Trading Activity
BOLT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $5,670 | 4 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Nemec Sarah | Senior VP, Finance and PAO | 2 | $2,835 | 0 | $0 | $2,835 |
| Quinn William P. | President, CEO and CFO | 2 | $2,835 | 0 | $0 | $2,835 |
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Insider Activity of Bolt Biotherapeutics, Inc.
Over the last 12 months, insiders at Bolt Biotherapeutics, Inc. have bought $5,670 and sold $0 worth of Bolt Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Bolt Biotherapeutics, Inc. have bought $9.3M and sold $622,818 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nemec Sarah (Senior VP, Finance and PAO) — $2,835. Quinn William P. (President, CEO and CFO) — $2,835.
The last purchase of 2,500 shares for transaction amount of $1,241 was made by Quinn William P. (President, CEO and CFO) on 2024‑12‑16.
List of Insider Buy and Sell Transactions, Bolt Biotherapeutics, Inc.
| 2024-12-16 | Quinn William P. | President, CEO and CFO | 2,500 0.0064% | $0.50 | $1,241 | -14.63% | ||
| 2024-12-16 | Nemec Sarah | Senior VP, Finance and PAO | 2,500 0.0064% | $0.50 | $1,241 | -14.63% | ||
| 2024-06-06 | Quinn William P. | President, CEO and CFO | 2,500 0.0065% | $0.64 | $1,594 | -21.68% | ||
| 2024-06-06 | Nemec Sarah | Senior VP, Finance and PAO | 2,500 0.0065% | $0.64 | $1,594 | -21.68% | ||
| 2023-12-12 | Quinn William P. | Chief Financial Officer | 7,500 0.0291% | $0.95 | $7,125 | -23.88% | ||
| 2023-12-06 | Quinn William P. | Chief Financial Officer | 2,500 0.008% | $0.78 | $1,955 | -17.59% | ||
| 2023-11-30 | Sale | ENGLEMAN EDGAR | director | 123,079 0.4308% | $0.86 | $105,614 | -10.81% | |
| 2023-11-29 | Sale | ENGLEMAN EDGAR | director | 25,805 0.0954% | $0.91 | $23,379 | -14.83% | |
| 2023-11-21 | Sale | ENGLEMAN EDGAR | director | 1,943 0.0071% | $0.90 | $1,751 | -10.77% | |
| 2023-11-21 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 3,400 0.0125% | $0.90 | $3,060 | -10.77% | |
| 2023-11-20 | Sale | ENGLEMAN EDGAR | director | 31,257 0.1173% | $0.92 | $28,756 | -15.31% | |
| 2023-11-20 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 54,700 0.2053% | $0.92 | $50,324 | -15.31% | |
| 2023-11-17 | Sale | ENGLEMAN EDGAR | director | 9,345 0.0354% | $0.93 | $8,691 | -16.40% | |
| 2023-11-17 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 16,354 0.062% | $0.93 | $15,209 | -16.40% | |
| 2023-11-16 | Sale | ENGLEMAN EDGAR | director | 8,571 0.0336% | $0.96 | $8,228 | -16.84% | |
| 2023-11-16 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 15,000 0.0587% | $0.96 | $14,400 | -16.84% | |
| 2023-06-06 | Quinn William P. | Chief Financial Officer | 1,829 0.0088% | $1.18 | $2,161 | -31.48% | ||
| 2022-07-13 | Sale | Novo Holdings A/S | 800,000 6.5259% | $2.00 | $1.6M | -40.32% | ||
| 2021-12-08 | Quinn William P. | Chief Financial Officer | 5,000 0.0962% | $4.71 | $23,575 | -56.78% | ||
| 2021-12-06 | Quinn William P. | Chief Financial Officer | 35 0.0007% | $4.64 | $162 | -55.82% |
Insider Historical Profitability
| Quinn William P. | President, CEO and CFO | 41272 0.1076% | $12,092.70 | 9 | 0 | <0.0001% |
| Nemec Sarah | Senior VP, Finance and PAO | 16633 0.0434% | $4,873.47 | 2 | 0 | |
| Novo Holdings A/S | 3703991 9.661% | $1.09M | 1 | 1 | <0.0001% | |
| HEALY JAMES | director | 2754437 7.1843% | $807,050.04 | 1 | 0 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2754437 7.1843% | $807,050.04 | 1 | 0 | <0.0001% |
| SHAH MAHENDRA | director | 1448286 3.7775% | $424,347.80 | 0 | 1 | |
| ENGLEMAN EDGAR | director | 251522 0.656% | $73,695.95 | 1 | 7 | <0.0001% |
| Vivo Capital VIII, LLC | 10 percent owner | 111662 0.2912% | $32,716.97 | 1 | 5 | <0.0001% |
| Schatzman Randall C | Chief Executive Officer | 1500 0.0039% | $439.50 | 1 | 0 | <0.0001% |
| Perez Edith A. | Chief Medical Officer | 1328 0.0035% | $389.10 | 2 | 0 | <0.0001% |
| LAPORTE KATHLEEN | director | 1200 0.0031% | $351.60 | 1 | 0 | <0.0001% |
| Khanna Ashish Siri Ram | director | 1200 0.0031% | $351.60 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$1,848,072 | 66 | -14.67% | $12.08M | |
$95,303,339 | 30 | -13.78% | $10.49M | |
$4,368,362 | 28 | -22.35% | $11.29M | |
$894,733 | 27 | -16.65% | $9.58M | |
$114,371,781 | 18 | -1.31% | $10.62M | |
$29,469,413 | 18 | 30.40% | $10.29M | |
$112,810,270 | 18 | -1.20% | $12.56M | |
Bolt Biotherapeutics, Inc. (BOLT) | $37,194,483 | 17 | -51.30% | $11.23M |
$51,865 | 17 | -38.70% | $8.79M | |
$941,975 | 12 | -10.74% | $12.63M | |
$389,864 | 11 | 12.52% | $13.28M | |
$8,971,546 | 8 | 6.18% | $9.76M | |
$1,028,395 | 4 | -11.91% | $11.68M | |
$149,611 | 4 | -25.43% | $9.09M | |
$45,953 | 2 | -2.14% | $13.1M | |
$31,190 | 2 | -14.18% | $12.63M | |
$5,512,500 | 1 | -7.91% | $12.29M | |
$19,863 | 1 | 144.27% | $9.78M | |
$25,173 | 1 | -68.88% | $9.83M |
BOLT Institutional Investors: Active Positions
| Increased Positions | 13 | +30.23% | 499,486 | +2.65% |
| Decreased Positions | 14 | -32.56% | 1M | -7.06% |
| New Positions | 7 | New | 326,912 | New |
| Sold Out Positions | 7 | Sold Out | 1M | Sold Out |
| Total Postitions | 42 | -2.33% | 18M | -4.41% |
BOLT Ownership Change vs Market
Institutional Investor Ownership
| Tang Capital Management Llc | $1,346.00 | 10.03% | 3.81M | 0 | 0% | 2024-12-31 |
| Vivo Capital, Llc | $1,243.00 | 9.27% | 3.52M | 0 | 0% | 2024-12-31 |
| Sofinnova Investments, Inc. | $972.00 | 7.25% | 2.75M | 0 | 0% | 2024-12-31 |
| Pivotal Bioventure Partners Investment Advisor Llc | $668.00 | 4.98% | 1.89M | 0 | 0% | 2024-12-31 |
| Nan Fung Group Holdings Ltd | $412.00 | 3.07% | 1.17M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $377.00 | 2.81% | 1.07M | 0 | 0% | 2024-12-31 |
| Samsara Biocapital, Llc | $370.00 | 2.76% | 1.05M | 0 | 0% | 2024-12-31 |
| Board Of Trustees Of The Leland Stanford Junior University | $254.00 | 1.89% | 719,546 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $120.00 | 0.9% | 340,674 | -11,752 | -3.33% | 2024-12-31 |
| Renaissance Technologies Llc | $107.00 | 0.8% | 302,039 | +8,000 | +2.72% | 2024-12-31 |